Innovus Pharmaceuticals (OTCMKTS:INNVD) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Innovus Pharmaceuticals (OTCMKTS:INNVD) issued its quarterly earnings data on Monday, April 1st. The company reported ($0.99) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.11) by $0.12, Morningstar.com reports. The firm had revenue of $4.75 million for the quarter, compared to analysts’ expectations of $8.13 million. Innovus Pharmaceuticals had a negative net margin of 34.51% and a negative return on equity of 682.54%.

OTCMKTS INNVD traded down $0.16 during trading hours on Wednesday, hitting $3.59. The company’s stock had a trading volume of 4,005 shares, compared to its average volume of 17,924. Innovus Pharmaceuticals has a twelve month low of $1.50 and a twelve month high of $19.37. The firm has a market capitalization of $8.47 million, a P/E ratio of -0.86 and a beta of 2.89.

Separately, ValuEngine cut shares of Innovus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, April 1st.

ILLEGAL ACTIVITY WARNING: “Innovus Pharmaceuticals (OTCMKTS:INNVD) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS” was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/24/innovus-pharmaceuticals-innvd-releases-earnings-results-beats-estimates-by-0-12-eps.html.

Innovus Pharmaceuticals Company Profile

Innovus Pharmaceuticals, Inc, a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality.

Recommended Story: How are dividend achievers different from dividend aristocrats?

Earnings History for Innovus Pharmaceuticals (OTCMKTS:INNVD)

Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.